Roundtable Discussions: Barriers in Giving Therapies in Relapsed/ Refractory DLBCL
September 21st 2021During a Targeted Oncology Case-Based Roundtable event, John M. Burke, MD, discussed the challenges with treating relapsed or refractory diffuse large B-cell lymphoma with a group of peers.
Usmani Considers Possible Treatments for a Patient With Relapsed/Refractory Multiple Myeloma
September 14th 2021Two year after being diagnosed with stage II multiple myeloma, a 78-year-old female patient was still receiving daratumumab plus lenalidomide maintenance and presented with mild fatigue during a routine follow-up.